163 related articles for article (PubMed ID: 1496338)
1. [Various molecular mechanisms involved in the pathogenesis of type II diabetes and their potential therapeutic importance].
Waeber G; Nicod P
Schweiz Med Wochenschr; 1992 Jul; 122(30):1109-16. PubMed ID: 1496338
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-1 structure, function and potential use for NIDDM.
Gefel D; Barg Y; Zimlichman R
Isr J Med Sci; 1997 Oct; 33(10):690-5. PubMed ID: 9397146
[TBL] [Abstract][Full Text] [Related]
3. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
Lam NT; Kieffer TJ
Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1.
Doyle ME; Egan JM
Recent Prog Horm Res; 2001; 56():377-99. PubMed ID: 11237222
[TBL] [Abstract][Full Text] [Related]
5. Transfection of pancreatic-derived beta-cells with a minigene encoding for human glucagon-like peptide-1 regulates glucose-dependent insulin synthesis and secretion.
Hui H; Yu R; Bousquet C; Perfetti R
Endocrinology; 2002 Sep; 143(9):3529-39. PubMed ID: 12193567
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes.
Ahrén B
Bioessays; 1998 Aug; 20(8):642-51. PubMed ID: 9780839
[TBL] [Abstract][Full Text] [Related]
7. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1.
Holst JJ
Diabetes Metab Res Rev; 2002; 18(6):430-41. PubMed ID: 12469357
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential.
Gromada J; Brock B; Schmitz O; Rorsman P
Basic Clin Pharmacol Toxicol; 2004 Dec; 95(6):252-62. PubMed ID: 15569269
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDM.
Thorens B; Waeber G
Diabetes; 1993 Sep; 42(9):1219-25. PubMed ID: 8349031
[TBL] [Abstract][Full Text] [Related]
10. Human studies with glucagon-like-peptide-1: potential of the gut hormone for clinical use.
Byrne MM; Göke B
Diabet Med; 1996 Oct; 13(10):854-60. PubMed ID: 8911778
[TBL] [Abstract][Full Text] [Related]
11. Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models.
Villanueva-Peñacarrillo ML; Puente J; Redondo A; Clemente F; Valverde I
Endocrine; 2001 Jul; 15(2):241-8. PubMed ID: 11720253
[TBL] [Abstract][Full Text] [Related]
12. Is glucagon-like peptide 1 an incretin hormone?
Nauck MA
Diabetologia; 1999 Mar; 42(3):373-9. PubMed ID: 10096792
[TBL] [Abstract][Full Text] [Related]
13. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
[TBL] [Abstract][Full Text] [Related]
14. Unique characteristics of the geriatric diabetic population and the role for therapeutic strategies that enhance glucagon-like peptide-1 activity.
Thearle M; Brillantes AM
Curr Opin Clin Nutr Metab Care; 2005 Jan; 8(1):9-16. PubMed ID: 15585995
[TBL] [Abstract][Full Text] [Related]
15. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
[TBL] [Abstract][Full Text] [Related]
16. Engineered beta-cells secreting dipeptidyl peptidase IV-resistant glucagon-like peptide-1 show enhanced glucose-responsiveness.
Islam MS; Rahman SA; Mirzaei Z; Islam KB
Life Sci; 2005 Jan; 76(11):1239-48. PubMed ID: 15642594
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 and islet lipolysis.
Sörhede Winzell M; Ahrén B
Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
Nauck MA; Meier JJ
Regul Pept; 2005 Jun; 128(2):135-48. PubMed ID: 15780433
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells.
Wang Y; Egan JM; Raygada M; Nadiv O; Roth J; Montrose-Rafizadeh C
Endocrinology; 1995 Nov; 136(11):4910-7. PubMed ID: 7588224
[TBL] [Abstract][Full Text] [Related]
20. Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1.
Bulotta A; Hui H; Anastasi E; Bertolotto C; Boros LG; Di Mario U; Perfetti R
J Mol Endocrinol; 2002 Dec; 29(3):347-60. PubMed ID: 12459036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
